Study of BAFF-R CAR-T cells for CD19-negative B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell lymphoma that is CD19-negative and has returned or not responded to at least two rounds of treatment.
- Your tumor cells must have the BAFF-R protein on them (a simple test can check this).
- You are well enough to walk and care for yourself (ECOG score 2 or less).
- Your kidneys, liver, lungs, and heart are working adequately based on blood tests and imaging.
- You are not pregnant, breastfeeding, or planning pregnancy for 6 months, and have no active infections like hepatitis B or C or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a new CAR-T cell treatment that targets a protein called BAFFR on cancer cells. It is for people with B-cell lymphoma that has come back or not responded to previous treatments.
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.